Acumen Q2 net loss expands to $20.5M; Phase 2 AD trial enrollment ahead of expectations

Acumen Pharmaceuticals, Inc.

2024-Q2 EPS reported -$0.59

Net loss $20.5M in Q2 2024 vs $11.6M in Q2 2023; R&D spending rose to $19.5M (from $9.1M) on ALTITUDE-AD costs.
Cash, equivalents, and securities $281.4M at June 30, 2024 (down from $306.1M at Dec 31, 2023); runway into H1 2027.
Phase 2 ALTITUDE-AD enrollment faster than expected; over 50 sites activated in U.S., Canada, U.K., EU.
Phase 1 subcutaneous sabirnetug study dosed first subject July 2024; topline data expected Q1 2025.
Virtual R&D Day planned Oct 2, 2024, to detail sabirnetug science and Phase 1 results.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.